Latest International Growth News

BLS Pharmaceuticals capped FY26 with record revenue and EBITDA, boosted by international expansion and major contracts, setting the stage for further growth in FY27.

I Synergy Group has appointed Anson Heng as Executive Chairman and Managing Director to spearhead its strategic cooperation with Macau Direch, formalised through a non-binding MoU targeting blockchain, AI, and digital asset initiatives.

Atomo Diagnostics reported a 40% increase in FY26 revenue to $5.3 million, driven by a surge in HIV self-test sales and new OEM customer orders. The company is advancing its syphilis and liver test developments while enhancing manufacturing capacity.

Activeport signs GOIP Globalnet to its Global Edge network, marking the third international carrier deal in a week and reinforcing its strategy for recurring revenue growth.

SPC Global reported solid Q4 FY26 growth driven by domestic beverage sales and a 50.8% jump in international revenue, while a $100 million equity raise slashed net leverage and paved the way for improved cash flow in FY27.

Biome Australia has posted a 30% increase in FY26 sales revenue to $23.9 million, driven by strong domestic demand and strategic moves into onshore manufacturing and international markets.

RTO Limited reported a net loss of NZD 173,831 for the year ended 31 March 2026, remaining inactive while actively seeking a reverse takeover target. The company faces going concern uncertainty but secured shareholder support with a $200k loan agreement post-year-end.

The Calmer Co. has won Coles' approval for its innovative Fiji Kava® FZZR™ product, extending its Australian supermarket reach while gearing up for a broader U.S. retail rollout supported by a key brokerage partnership.

AFT Pharmaceuticals surged 22% to NZ$254.7 million revenue in FY26, surpassing profit guidance and securing FDA approval to advance a pivotal injectable iron Phase III trial targeting a $7.4 billion market. The company is poised for further global expansion and product launches in FY27.

AFT Pharmaceuticals delivered a 22% revenue jump in FY26 to NZD 254.7 million, surpassing profit guidance and expanding its footprint to 87 countries. The company is advancing multiple R&D projects, including a pivotal Phase III injectable iron trial, while targeting over NZD 300 million in revenue for FY27.

Monash IVF lowers its FY26 underlying NPAT guidance to $17-18 million, citing a 4.7% drop in Australian stimulated IVF cycles. Despite this, the company has expanded its national market share to 20.1% and seen international volume growth.

Marlin Global’s portfolio lagged the broader market in May 2026, weighed down by semiconductor underexposure and near-term revenue challenges in key holdings, while AI-focused stocks powered a narrow rally.